摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(-)-Ifosfamide | 66849-33-0

中文名称
——
中文别名
——
英文名称
(-)-Ifosfamide
英文别名
(+)-(R)-ifosphamide;(S)-ifosfamide;(R)-ifosfamide;(S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide;(2S)-N,3-bis(2-chloroethyl)-2-oxo-1,3,2λ5-oxazaphosphinan-2-amine
(-)-Ifosfamide化学式
CAS
66849-33-0
化学式
C7H15Cl2N2O2P
mdl
——
分子量
261.088
InChiKey
HOMGKSMUEGBAAB-AWEZNQCLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    41.6
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Lipase as a Chiral Selector Immobilised on Carboxylated Single-Walled Carbon Nanotubes and Encapsulated in the Organic Polymer Monolithic Capillary for Nano-High Performance Liquid Chromatography Enantioseparation of Racemic Pharmaceuticals
    作者:Ali Fouad、Frady G. Adly、Moustafa K. Soltan、Ashraf Ghanem
    DOI:10.3390/molecules28186663
    日期:——

    Herein, we report the preparation of lipase immobilised on single-walled carbon nanotubes (SWCNTs) as an enantioselector for capillary monolithic columns and their application in the chiral separation of racemic pharmaceuticals. The columns were prepared through the encapsulation of functionalised SWCNTs (c-SWCNTs) within an organic monolithic polymer, followed by the immobilisation of lipase over the obtained monolith, over a three-day (L1) and five-day (L2) period. The prepared columns were tested for the enantioselective nano-HPLC separation of 50 racemic drugs. A suitable resolution was achieved for 25 drugs using nano-RP-HPLC conditions for both the L1 and L2 capillaries, while no specific resolution was detected under normal-phase HPLC conditions. The developed c-SWCNT-lipase-based polymeric monolithic capillaries are a promising expansion for separating pharmaceutical enantiomers’ using nano-HPLC.

    在此,我们报告了固定在单壁碳纳米管(SWCNTs)上的脂肪酶作为毛细管整体柱对映体选择器的制备及其在手性分离外消旋药物中的应用。制备色谱柱的方法是将功能化的 SWCNTs(c-SWCNTs)封装在有机整体聚合物中,然后在获得的整体上固定脂肪酶,固定时间分别为三天(L1)和五天(L2)。对制备的色谱柱进行了对映体选择性纳米高效液相色谱分离 50 种外消旋药物的测试。在 L1 和 L2 两种毛细管的纳米RP-HPLC 条件下,对 25 种药物进行了适当的分辨,而在正相 HPLC 条件下未检测到特定的分辨。所开发的基于 c-SWCNT 脂肪酶的聚合物整体毛细管是利用纳米高效液相色谱分离药物对映体的一种很有前景的扩展方法。
  • MASUREL, DOMINIQUE;WAINER, IRVING W., J. CHROMATOGR. BIOMED. APPL., 490,(1989) N, C. 133-143
    作者:MASUREL, DOMINIQUE、WAINER, IRVING W.
    DOI:——
    日期:——
  • MISIURA, KONRAD;KINAS, RYSZARD W.;STEC, WOJCIECH J.;KUSNIERCZYK, HALINA;R+, J. MED. CHEM., 31,(1988) N 1, 226-230
    作者:MISIURA, KONRAD、KINAS, RYSZARD W.、STEC, WOJCIECH J.、KUSNIERCZYK, HALINA、R+
    DOI:——
    日期:——
查看更多

同类化合物

曲磷胺 曲磷胺 异环磷酰胺杂质F 异环磷酰胺 [(2-羟基-2-氧代-1,4,2-氧氮杂磷杂环己烷-4-基)甲基]膦酸 4-过氧化氢异环磷酰胺 4-氧代异环磷酰胺 4-乙基-7-甲基-7-氮杂-2,6-二氧杂-1-磷杂双环[2.2.2]辛烷1-硫化物 2’-氧代异环磷酰胺 2-[2-氯乙基-[3-(2-氯乙基)-2-氧代-1-氧杂-3-氮杂-2-磷杂环己-2-基]氨基]乙基甲烷磺酸酯 2,3,4,6,7,8-六氢-[1,3,2]氧氮杂膦咛并[2,3-b][1,3,2]氧氮杂膦咛 (2-氯-乙基)-[(R)-3-(2-氯-乙基)-2-氧代-2lambda5-[1,3,2]氧氮杂磷杂环己烷-2-基]-胺 (2R*,4aS*,8aR*)-1-methyl-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2S*,4aS*,8aR*)-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2R*,4aS*,8aS*)-1-methyl-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2S*,4aS*,8aS*)-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (S,S)-2-oxo-2-propionyl-1,3,2-oxaphosphorinane 2-(Dimethylamino)-3-phenyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3,5,5-trimethyl-1,3,2-oxazaphosphorinane cis-2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-methyl-5-tert-butyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-methyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-phenyl-1,3,2-oxazaphosphorinane 3,3,5,5-tetramethyl-2-oxido-2-oxo-1,4,2-oxaazaphosphorinane 2-(2-chloroethylamino)-3-(1-methyl-2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 4-ethyl-2-hydroxy-2-oxo-tetrahydro-4H-1,4,2-oxazaphosphorine geranyloxyifosfamide 4-methoxy-ifosfamide (2-chloroethyl)-[3-(2-chloroethyl)-2-oxo-4-pentyloxy-2λ5-[1,3,2]oxazaphosphinan-2-yl]amine 3-ethyl-2-hydroxy-2-oxo-1,4,2-oxazaphosphorinane Methyl-[3-(3-methyl-[1,3,2]oxazaphosphinan-2-yloxy)-propyl]-amine 2-Oxo-3-(propan-2-yl)-1,3,2-oxazaphosphinan-2-ium 3-(2-Chloroethyl)-2-(2-chloroethyl)amino-4-hydroxytetrahydro-2H-1,3,2-oxazaphosphorine 3-(2-Chloroethyl)-2-(1-ethyl-2-mesyloxyethylamino)-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide 2H-1,3,2-Oxazaphosphorine, 2-fluorotetrahydro-3,5-dimethyl-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 2-fluorotetrahydro-3,4-dimethyl-, 2-oxide (3-Isopropyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-acetic acid methyl ester cis-2-mesityl-2-oxo-3-phenyl-5-tert-butyl-1,3,2λ5-oxazaphosphorinane trans-2-mesityl-2-oxo-3-phenyl-5-tert-butyl-1,3,2λ5-oxazaphosphorinane (2S,6S)-2-Benzyl-3-(1,1-diethyl-propyl)-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2R,6S)-2-Benzyl-3-(1,1-diethyl-propyl)-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2S,6S)-2-((E)-2-Allyloxy-but-2-enyl)-3-tert-butyl-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2R,6S)-2-((E)-2-Allyloxy-but-2-enyl)-3-tert-butyl-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (S)-(2l,6l)-2-(methoxymethyl)-6-methyl-3-(1-methylethyl)-1,3,2-oxazaphosphorinane 2-sulfide (S)-1-((2S,6S)-3-tert-Butyl-6-methyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-3-methyl-hex-5-en-2-one 2-methoxy-1,3,2-oxazaphosphinane 3-(2-Chloroethyl-2-<(2-chloroethyl)-(3-mesyloxytrimethylen)-amino>-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide 2-chloro-3-[(S)-α-methylbenzyl]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide (S)-(2u,6l)-3-(1,1-Diethylpropyl)-6-methyl-2-(2-propenyl)-1,3,2-oxazaphosphorinane 2-oxide 3-(2-chloro-ethyl)-2-(2-hydroxy-ethylamino)-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-one isopropyl-[3-(3-isopropyl-[1,3,2]oxazaphosphinan-2-yloxy)-propyl]-amine